Introduction: Metastatic colorectal cancer (mCRC) patients (pts) with liver-only disease (LOD) have different prognosis. The impact of primary tumor removal (PTR), liver resection (LR), inflammatory markers neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR) and baseline clinical and laboratory factors on prognosis in pts younger than 65 years with mCRC with LOD, treated with first line CAPOX and Bevacizumab was evaluated. Methods: Thirty clinical and laboratory parameters were evaluated. Correlation analyses (Persons' and Spearman' coefficients) and ANOVA were performed. All analyses were executed by SPSS 9.0 statistical system. Results: 29 mCRC with LOD (17/12- M/W) with mean age 43,7 y (range 30-65) were selected from pts' database. Mean lead time to diagnosis was 3,2 mo (1-12). Almost all pts (48,3%) completed first and second line of treatment, while 17,2% performed more than three lines. Seven pts had no PTR before 1st line chemo; 16 had liver resection; Mean PFS was 11,4 mo (4-27) and mean OS 19,9 mo (4-34). ANOVA results in better PFS in pts with LR comparing those without LR (13,1mo/9,4 mo, p = 0.043), while lack of PTR leads to shorted OS (8,7 mo/21,2 mo, p = 0.013). OS was longer in younger pts (<41y -27,4mo vs >41 y – 17,8 mo, p = 0,071). PTR was found to be correlated negatively with age (-0.52, p = 0.004) and colon localization (p = 0.027). Hb levels correlated strongly negatively with NLR (-0.51, p = 0.011) and with PLR (-0.55, p = 0.004). Lead time correlated negatively with N-stage (-0.47, p = 0.004) and T stage (-0.45, p = 0.004). Conclusion: LR and PTR positively affect survival while. mCRC with LOD younger than 41 y had better prognosis than older ones. Lead time had impact on N and T-stage. High levels of markers of systemic inflammation are connected with anemia in mCRC pts with LOD.